Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action

A. Barnett; S. Ding; C. Murray; M. Chamberlain; S. Plummer; T. R. J. Evans; I. MacPherson; D. Bissett; C. R. Elcombe; C. R. Wolf

doi:10.1016/S1359-6349(10)71828-0

Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action

A. Barnett
, S. Ding
, C. Murray
, M. Chamberlain
, S. Plummer
, T. R. J. Evans
, I. MacPherson
, D. Bissett
, C. R. Elcombe
, C. R. Wolf

Research output: Contribution to journal › Book/Film/Article review › peer-review

Original language	English
Pages (from-to)	45-46
Number of pages	2
Journal	EJC Supplements
Volume	8
Issue number	7
DOIs	https://doi.org/10.1016/S1359-6349(10)71828-0
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S1359-6349(10)71828-0

Cite this

Barnett, A., Ding, S., Murray, C., Chamberlain, M., Plummer, S., Evans, T. R. J., MacPherson, I., Bissett, D., Elcombe, C. R., & Wolf, C. R. (2010). Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 8(7), 45-46. https://doi.org/10.1016/S1359-6349(10)71828-0

@article{4f31139e1f714235bccae3230b84b2df,

title = "Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action",

author = "A. Barnett and S. Ding and C. Murray and M. Chamberlain and S. Plummer and Evans, \{T. R. J.\} and I. MacPherson and D. Bissett and Elcombe, \{C. R.\} and Wolf, \{C. R.\}",

year = "2010",

doi = "10.1016/S1359-6349(10)71828-0",

language = "English",

volume = "8",

pages = "45--46",

journal = "EJC Supplements",

issn = "1359-6349",

publisher = "Elsevier",

number = "7",

}

Barnett, A, Ding, S, Murray, C, Chamberlain, M, Plummer, S, Evans, TRJ, MacPherson, I, Bissett, D, Elcombe, CR & Wolf, CR 2010, 'Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action', EJC Supplements, vol. 8, no. 7, pp. 45-46. https://doi.org/10.1016/S1359-6349(10)71828-0

TY - JOUR

T1 - Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases

T2 - Human tumor xenograft efficacy and in vitro mode of action

AU - Barnett, A.

AU - Ding, S.

AU - Murray, C.

AU - Chamberlain, M.

AU - Plummer, S.

AU - Evans, T. R. J.

AU - MacPherson, I.

AU - Bissett, D.

AU - Elcombe, C. R.

AU - Wolf, C. R.

PY - 2010

Y1 - 2010

U2 - 10.1016/S1359-6349(10)71828-0

DO - 10.1016/S1359-6349(10)71828-0

M3 - Book/Film/Article review

SN - 1359-6349

VL - 8

SP - 45

EP - 46

JO - EJC Supplements

JF - EJC Supplements

IS - 7

ER -